第一项始终是图钉的来源。总体可信度是各份资料对上方所用开始和结束时间支持程度的加权平均；资料每比最新的一份旧 180 天，权重减半。
Lilly's release is datelined "INDIANAPOLIS, May 21, 2026" and says the company "today announced positive topline results from TRIUMPH-1".
STAT (Elaine Chen), 21 May 2026: Lilly reported Thursday that those on the highest dose who stayed on retatrutide lost 28.3% at 80 weeks; 11% on that dose discontinued for adverse events and the all-participants figure was 25%, against discontinuation of up to 7% in Wegovy and Zepbound pivotal trials.[1]
BioPharma Dive, 21 May 2026: results announced Thursday from Triumph-1, the largest and longest retatrutide trial; 2,339 participants, 28%/26%/19% weight loss on 12/9/4 mg vs 2% placebo, 25%/24%/18% counting discontinuations; RBC's Trung Huynh called it "a clean win"; data due at ADA next month.
AJMC (Giuliana Grossi), 21 May 2026: 2,339-participant trial, 70.3 lb (28.3%) mean loss on 12 mg at 80 weeks, 45.3% reaching at least 30% loss, 65.3% reaching BMI under 30, and 30.3% at 104 weeks in the 532-person extension.
TCTMD (Caitlin E. Cox), 21 May 2026: reports the Lilly topline results - 19.0%, 25.9% and 28.3% weight loss by dose at 80 weeks vs 2.2% placebo, 65.3% on 12 mg below BMI 30 - with detailed results due at the ADA Scientific Sessions in June 2026.
有遗漏或错误吗？用你自己的话说明：能佐证此图钉的链接、不同的开始或结束日期及理由，或缺失、有误的信息。AI 会对照此图钉的来源进行核实，搜索更好的来源，并添加任何支持你说法的页面。图钉自身的来源仍然最重要。